论文部分内容阅读
目的比较索拉非尼联合经动脉化疗栓塞(TACE)及索拉非尼单药治疗晚期肝细胞癌(HCC)的恶化时间(TTP)和总生存时间(OS)。方法本回顾性研究得到伦理委员会批
Objective To compare the time to progression (TTP) and overall survival (OS) of sorafenib combined with transcatheter arterial chemoembolization (TACE) and sorafenib in the treatment of advanced hepatocellular carcinoma (HCC). Methods This retrospective study was approved by ethics committee